Evaluation of a new transcutaneous bilirubinometer in newborn infants

Sci Rep. 2022 Apr 7;12(1):5835. doi: 10.1038/s41598-022-09788-4.

Abstract

To avoid brain damage in newborn infants, effective tools for prevention of excessive neonatal hyperbilirubinemia are needed. The objective of this study was to evaluate a new transcutaneous bilirubinometer (JAISY). For this purpose, 930 bilirubin measurements were performed in 141 newborn infants born near-term or at term (gestational age 35-41 weeks; postnatal age 1-6 days; 71 boys; including 29 infants with darker skin) and compared to those of a previously validated instrument (JM105). In each infant, the mean of three repeated measurements in the forehead was calculated for each instrument, followed by a similar measurement on the chest. The bilirubin values varied between 0 and 320 µmol/l (0-18.8 mg/dl). There was a high degree of agreement with significant correlations between bilirubin values measured with the two devices on the forehead (Pearson's r = 0.94, p < 0.001) and the chest (r = 0.94, p < 0.001). The correlations remained after stratifying the data by gestational age, postnatal age and skin color. The coefficient of variation for repeated bilirubin measurements was 8.8% for JAISY and 8.0% for JM105 (p = 0.79). In conclusion, JAISY provides accurate and reproducible information on low to moderately high bilirubin levels in newborn infants born near-term or at term.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bilirubin
  • Child
  • Child, Preschool
  • Gestational Age
  • Humans
  • Hyperbilirubinemia, Neonatal* / diagnosis
  • Infant
  • Infant, Newborn
  • Jaundice, Neonatal* / diagnosis
  • Male
  • Neonatal Screening
  • Skin Pigmentation

Substances

  • Bilirubin